No Data
No Data
Neurocrine Wins FDA Nod for CAH Therapy
Weekly Buzz: Tech stocks hit high scores on ominous day
Sector Update: Health Care Stocks Edge Higher Late Afternoon
Centene Stock Undervalued After Clarity Emerges on Post-ACA Subsidy Expiration, UBS Says
Unusual Options Activity: PINS, BRKR and Others Attract Market Bets, PINS V/OI Ratio Reaches 892.9
Centene Shares Are Trading Higher After the UBS Upgraded the Stock From Neutral to Buy and Raised Its Price Target From $79 to $80. Also, Barclays Maintained an Overweight Rating on the Stock and Raised Its Price Target From $91 to $93.
loading...
104134049 : no clue too… entered at 70
WALLSTREETBAGS : Bear market currently
103320647 OP WALLSTREETBAGS : Took only one day and it became bear market